Brown/LUNGevity Award for Immunotherapy Resistance

The 2024 Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy is now open for application submissions.

The Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy will fund high-impact research that seeks to understand resistance to first-line immunotherapy and develop therapeutic strategies targeting this resistance. The program has no geographical restrictions and is open to both US and non-US applicants.

Award Guidelines

• Applicants must hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university, and have completed a postdoctoral training fellowship.
• Awards may be for a maximum of $500,000 ($250,000 per year for 2 years)
• Annual milestones must be met

Note: LUNGevity will grant only one award per institution.

LUNGevity uses a two-step application process:

1. A letter of intent (LOI), with a brief overview of the proposed project and biographical information
2. A full application with an extended narrative about the project, as well as supporting information and documentation. (Because the number of awards is limited, only a subset of applicants will be invited to submit a full application after the LOI review is completed.)

Reviewers are drawn from LUNGevity's Scientific Advisory Board and other lung cancer experts. Awardees have progress and financial reporting obligations during their award term.

A complete description of the award, terms and conditions, and instructions are included in the 2024 Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy RFA. All application materials must be submitted electronically via  proposalCENTRAL.

2024 Award Timeline